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Abstract
TGFb-activated kinase 1 (TAK1), a member of the mitogen-activated protein kinase kinase kinase (MAP3K) family, is
considered a key intermediate in a multitude of innate immune signaling pathways. Yet, the specific role of TAK1 in the
myeloid compartment during inflammatory challenges has not been revealed. To address this question, we generated
myeloid-specific kinase-dead TAK1 mutant mice. TAK1 deficiency in macrophages results in impaired NF-kB and JNK
activation upon stimulation with lipopolysaccharide (LPS). Moreover, TAK1-deficient macrophages and neutrophils show an
enhanced inflammatory cytokine profile in response to LPS stimulation. Myeloid-specific TAK1 deficiency in mice leads to
increased levels of circulating IL-1b, TNF and reduced IL-10 after LPS challenge and sensitizes them to LPS-induced
endotoxemia. These results highlight an antiinflammatory role for myeloid TAK1, which is essential for balanced innate
immune responses and host survival during endotoxemia.
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Introduction
TGFb-activated kinase 1 (TAK1) was originally identified as a
key regulator of TGFb/bone morphogenetic protein signaling [1].
Since then a wealth of information has been generated placing
TAK1 as part of a more complex signaling network that governs
basic cellular activities. Studies using complete and conditional
TAK1 knockout mice revealed that TAK1 integrates signals
emanating from TGFb, TNF, IL-1b, Toll-like receptors (TLRs),
B-cell receptors and T-cell receptors, to coordinate homeostasis
and immunity, and that its absence can lead to carcinogenesis,
inflammation or death [2–13]. In Drosophila, TAK1 is critical for
antibacterial innate immunity as TAK1 mutants are highly
susceptible to Gram-negative bacterial infection and do not
produce antibacterial peptides [14]. In mammals, there are
several lines of evidence supporting a critical role for TAK1 in
innate immunity [8,11,15]. Genetic evidence demonstrating a role
for TAK1 during innate immunoreceptor signaling has been
obtained in mature immune cells by using B cell-specific TAK1-
deficient mice [8]. TAK1-deficient B cells fail to activate
transcription factor NF-kB and mitogen-activated protein kinases
(MAPKs) in response to TLR ligands and have impaired
production of IL-6, supporting an evolutionary conserved role
for TAK1 in innate immunity. However, the role of TAK1 during
TLR innate immune responses has not been addressed in the main
cellular mediators of innate immunity, the myeloid cells.
Myeloid cells (macrophages and neutrophils) are the chief
cellular agents of the inflammatory cascade during microbial
infection. They initiate coordinated innate immune defenses
through activation of pathogen recognition receptors that
recognize specific pathogen-associated molecular patterns [16].
As a result of these interactions, immune cellular activation occurs
with the release of cytokine and non-cytokine mediators. A key
event in the immune response to Gram-negative bacteria is the
recognition of lipopolysaccharide (LPS) by TLR4 [17]. LPS plays
a key role in Gram-negative sepsis by inducing production of
proinflammatory and antiinflammatory mediators, the most
critical being IL-1b, TNF, IL-6 and IL-10 [18]. Cytokine
production significantly influences the quality, duration, and
magnitude of most inflammatory reactions.
During LPS-induced endotoxemia, serine/threonine kinase
cascades are activated with pleiotropic downstream effects that
include activation of protein kinases such as the MAPKs and the I-
kB kinases. Although key molecules in these signaling pathways
have been identified, there are still substantial gaps in our
knowledge, including the role of members of the MAPK kinase
kinase (MAP3K) family. Here we investigated the myeloid-specific
role of the MAP3K TAK1 during LPS inflammatory responses.
TAK1 deficiency in macrophages led to impaired activation of
NF-kB and JNK following LPS stimulation, identifying TAK1 as
an important upstream signaling molecule that regulates LPS-
induced NF-kB and JNK activation in macrophages. Cytokine
profile analysis of TAK1-deficient macrophages upon stimulation
with LPS, revealed a hyperinflammatory phenotype characterized
by increased proinflammatory (IL-1b, TNF, and IL-6) and
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inflammatory cytokine profile was observed in LPS-stimulated
neutrophils, although no reduction in IL-10 production was
observed. Consistent with the above, mice with defective myeloid
TAK1 mount an enhanced innate immune response to LPS by
exhibiting increased circulating levels of IL-1b and TNF, reduced
IL-10, and subsequently significantly increased mortality to LPS-
induced shock. We conclude that myeloid TAK1 acts by
regulating the balance between proinflammatory and antiinflam-
matory cytokine production thereby preventing unrestrained
inflammatory responses.
Results and Discussion
Generation of ubiquitous and myeloid-specific TAK1
mutant mice
We generated mice with conditional expression of a Map3k7
allele encoding a kinase-dead truncated form of TAK1, following a
similar targeting strategy to previous studies [8]. The targeting
vector was constructed by placing two loxP sites flanking exon 2 of
Map3k7 (Fig. 1A). Exon 2 encodes part of the kinase domain
including the ATP binding pocket and can be deleted without
disrupting the remainder of the reading frame. To generate mice
that ubiquitously express the truncated TAK1 (Map3k7
2/2 mice),
we crossed Map3k7
flox/flox mice with transgenic mice expressing
Cre in germ cells [19]. Of 101 newborn pups (19 litters) obtained
by intercrossing Map3k7
+/2 mice, we had 71 Map3k7
+/2,3 0
Map3k7
+/+ and no Map3k7
2/2 mice, confirming previous studies
that TAK1 deficiency leads to embryonic lethality [4,8,11].
To investigate the role of myeloid-specific TAK1 in innate
immunity, we crossed Map3k7
flox/flox mice with LysM-Cre knockin
mice, which express the Cre recombinase in macrophages and
neutrophilic granulocytes [20]. This resulted in a 50% deletion in
macrophages as it was assessed by Southern blot analysis of DNA
extracted from bone marrow-derived macrophages (BMDMs)
(Fig. 1B). Additionally, PCR analysis was performed on FACS-
sorted CD11b
+F4/80
+ resident peritoneal macrophages and
CD11b
+Gr1
+ splenic neutrophils for an approximate indication
of deletion, suggesting a similar percentage of deletion in the
macrophage population, while a higher deletion percentage was
observable in neutrophils (Fig. 1C). Mice with myeloid-restricted
TAK1 deficiency (Map3k7
Dmyel) were born at the expected
Mendelian ratio, developed normally, and did not show any
gross morphological changes in the overall histology of lymphoid
organs and other organs rich in myeloid cells, such as the
gastrointestinal tract (data not shown). In the control groups, we
observed no phenotypic difference among Map3k7
flox/flox and
LysM-Cre mice and thus Map3k7
flox/flox mice were used as
controls.
To determine if TAK1 deficiency affected the production of
immature and mature myeloid cell subsets, we performed flow
cytometric immunophenotypical analysis of bone marrow (BM)
[21,22], peripheral blood, spleen and peritoneal cavity cell
preparations obtained from Map3k7
Dmyel and Map3k7
flox/flox mice.
We observed no differences in the immature myeloid cell subsets
in the BM of Map3k7
Dmyel and Map3k7
flox/flox mice as there were
similar frequencies of common myeloid progenitors, granulocyte/
macrophage progenitors and the myelomonocytic cell fraction
(fraction of Gr-1
+/Mac-1
+ cells) (Table 1). In peripheral blood
there were similar numbers of monocytes and neutrophils between
Map3k7
Dmyel and Map3k7
flox/flox cell preparations (Table 1). Also,
no statistically significant differences were observed in the number
of peripheral splenic macrophages and neutrophils, nor in the
number of resident peritoneal macrophages (Table 1).
We next investigated the ability of myeloid precursor cells to
differentiate into macrophages and granulocytes in colony-forming
assays upon stimulation with G-CSF, M-CSF, and GM-CSF. As
shown in Fig. 1D, the numbers of colonies grown from
Map3k7
Dmyel and Map3k7
flox/flox BM cells were comparable,
suggesting that myeloid TAK1 deficiency did not affect the
developmental potential of early myeloid precursor cells. It
has been reported that TAK1 promotes survival signals in
hematopoietic cells [12]. Nevertheless, we and others [15] did
not observe any reduction in the numbers of macrophages and
granulocytes in the periphery when TAK1 is inactivated in
myeloid cells.
TAK1 deficiency promotes a hyperinflammatory
phenotype in LPS-stimulated macrophages and
neutrophils
We focused our subsequent analyses on identifying the role of
TAK1 in LPS-induced inflammatory responses. For these studies
we prepared BMDMs from Map3k7
Dmyel and Map3k7
flox/flox
littermate mice and treated them with 100 ng/ml LPS.
Map3k7
Dmyel BMDMs exhibited reduced NF-kB (Fig. 2A) and
JNK activation (Fig. 2B), consistent with similar studies in mouse
monocytic cell lines for JNK activation [15], but also in other cell
types such as B cells [8] and MEFs [11]. Next, we performed a
detailed kinetic analysis of cytokine production upon LPS
stimulation. TAK1 deficiency resulted in increased IL-1b, TNF,
and IL-6, and decreased IL-10 production following LPS
stimulation at different time points (Fig. 3A, B, C, D). A
substantial increase in IL-1b production was evident at all time
points up to 12 h post stimulation in Map3k7
Dmyel BMDMs
compared to control cells, whereas at 24 h, IL-1b declined to
almost undetectable levels in both Map3k7
Dmyel and Map3k7
flox/flox
cells (Fig. 3A). Increased production of TNF and IL-6 was also
observed at early time points after LPS stimulation in Map3k7
Dmyel
BMDMs (Fig. 3B, C). In contrast, IL-10 production was almost 4-
fold lower 3 h post LPS stimulation in Map3k7
Dmyel BMDMs
compared to control cells, and a significant reduction was still
evident until 24 h (Fig. 3D). Thus upon LPS stimulation,
Map3k7
Dmyel BMDMs exhibit a hyperinflammatory phenotype.
It was previously shown that upon LPS stimulation, reduced
NF-kB activation in IKKb-deficient macrophages leads to
increased IL-1b production due to enhanced IL-1b processing
[23]. Therefore, reduced NF-kB activation in TAK1-deficient
macrophages could at least partly account for the increased IL-1b
production observed. Interestingly, a recent study revealed a
regulatory loop for the induction of IL-10 during the LPS response
which involves TAK1 and AUF1 [24]. Following LPS stimulation,
the RNA-binding protein AUF1 maintains proper levels of TAK1
by post-transcriptional control on Tak1 mRNA and in this way
accomplishes proper NF-kB activation required for the induction
of IL-10. Thus, in the absence of TAK1 several layers of
transcriptional and/or post-transcriptional controls may contrib-
ute to the observed deregulated cytokine profile.
As TAK1 is deleted in both macrophages and neutrophils in
Map3k7
Dmyel mice, we next sought to determine whether TAK1
deficiency caused a similar cytokine profile change in neutrophils
as in macrophages. For this we used thioglycollate-elicited
peritoneal neutrophils from Map3k7
Dmyel and Map3k7
flox/flox mice
and measured cytokine production 6 h and 12 h upon LPS
stimulation. Paralleling the results of macrophages, LPS induced
enhanced production of the proinflammatory cytokines IL-1b,
TNF and IL-6 in Map3k7
Dmyel peritoneal neutrophils (Fig. 3E, F,
G). Notably however no reduction in the levels of IL-10 was
observed in peritoneal neutrophils. In contrast, IL-10 production
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Dmyel compared to
Map3k7
flox/flox neutrophils (Fig. 3H), suggesting that different
mechanisms govern cytokine production in LPS-stimulated
macrophages and neutrophils as it has been already reported for
IL-1b production [23]. Interestingly, Map3k7
Dmyel peritoneal
neutrophils exhibited higher basal levels of TNF and IL-6
compared to almost undetectable levels in Map3k7
flox/flox neutro-
phils. Bearing in mind that thioglycollate-elicited neutrophils are
not in a steady state, this could imply a general mechanism of
deregulated cytokine production upon activation of myeloid cells,
in the absence of TAK1.
These results demonstrate that upon LPS stimulation, TAK1
deficiency alters the cytokine profile in macrophages and
neutrophils in favor of a proinflammatory profile. This is a quite
unexpected finding, as TAK1 is traditionally considered a
proinflammatory molecule [8,11]. In B cells, TAK1 deficiency
was reported to result in diminished IL-6 production upon
LPS stimulation [8]. Additional studies are required to delineate
the molecular pathways underlying the deregulated cytokine
production upon LPS stimulation in the absence of myeloid
TAK1.
Increased mortality to endotoxemia and deregulated
cytokine production in mice defective in myeloid TAK1
We next sought to investigate the pathophysiological signifi-
cance of the inflammatory phenotype exhibited by LPS-induced
macrophages and neutrophils. For this, mice were intraperitone-
ally (i.p.) challenged with 100 ı `g of LPS and serum samples were
obtained at various intervals (0, 1.5, 3, and 6 h) after injection, for
the assessment of the concentrations of circulating cytokines
(Fig. 4A, B, C, D). The induction of proinflammatory cytokines
was greatly enhanced in Map3k7
Dmyel mice compared to the
Map3k7
flox/flox control mice, consistent with the in vitro data. A
marked increase in IL-1b was observed already within the first
1.5 h, and continued to increase in the serum of Map3k7
Dmyel
mice, until it reached a peak concentration at 3 h that was 2-fold
higher than the amount detected in Map3k7
flox/flox mice (Fig. 4A).
The levels of serum TNF were also significantly higher in
Map3k7
Dmyel mice compared to Map3k7
flox/flox mice. TNF peaked
at 1.5 h both in Map3k7
Dmyel and Map3k7
flox/flox mice, but a 1.5-
fold increase was observed in the Map3k7
Dmyel mice after which,
TNF levels declined and by 6 h became identical in Map3k7
Dmyel
and Map3k7
flox/flox mice (Fig. 4B). Additionally, a trend towards an
Figure 1. Generation of conditional TAK1-deficient mice. (A) Schematic representation of the wild type, targeted, floxed and deleted Map3k7
genomic locus, indicating BamHI, SacI and XbaI restriction sites used for Southern blot. The Map3k7 locus comprises 17 exons; in the scheme the first
6 exons are represented. The probes used to verify homologous recombination at the 59 and 39 end are shown. Black arrows indicate loxP sites; red
arrows indicate FRT sites. B, BamHI; S, SacI; X, XbaI. (B) Southern blot of genomic DNA isolated from BMDMs after digestion with XbaI and using the 39
probe. (C) PCR analysis of genomic DNA isolated from FACS-sorted CD11b
+F4/80
+ resident peritoneal macrophages and CD11b
+Gr1
+ splenic
neutrophils. (D) Colony formation by BM cells from Map3k7
Dmyel and Map3k7
flox/flox mice in response to M-CSF, G-CSF and GM-CSF. Data are shown as
mean 6 SEM of 4 mice per group and are representative of two independent experiments.
doi:10.1371/journal.pone.0031550.g001
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reach statistical significance (Fig. 4C). In contrast to the
augmented production of proinflammatory cytokines, circulating
levels of the antiinflammatory IL-10 were significantly reduced in
the serum of Map3k7
Dmyel mice compared to the Map3k7
flox/flox
controls. At 1.5 h post LPS challenge, IL-10 levels were identical
but a more acute decline was observed in the serum of the
Map3k7
Dmyel mice at 3–6 h (Fig. 4D).
High circulating cytokine levels are associated with endotox-
emia and contribute to the increased mortality associated with this
condition. Map3k7
Dmyel mice and Map3k7
flox/flox littermates, as
well as LysM-Cre control mice, were i.p. challenged with a high
dose of LPS (20 mg/kg of body weight) and survival was
monitored for 72 h. In this acute inflammation model, death
occurs within a few days depending on the dose response to LPS.
Map3k7
Dmyel mice were indeed highly sensitive to LPS challenge,
as only 19% (3 out of 16) survived within 24 h, compared to a
survival rate of 93% (14 out of 15) for the Map3k7
flox/flox mice and
100% (5 out of 5) for the LysM-Cre control mice (Fig. 4E). Over a
period of 72 h, the survival of Map3k7
Dmyel mice was 12%,
significantly lower than the 50% survival of Map3k7
flox/flox mice
and 60% for LysM-Cre mice (Fig. 4E).
In conclusion, these data demonstrate that myeloid TAK1 is an
essential regulator of LPS-induced inflammatory responses.
Notably, an increased sensitivity to LPS-induced endotoxemia is
also observed in myeloid-specific IKKb-deficient mice [23].
Similarly, reduced NF-kB activation in the absence of TAK1
could account for the deregulated IL-1b production and the
resulting increase in sensitivity to LPS challenge. Yet, myeloid-
specific TAK1-deficiency also affects the production of other
cytokines (TNF, IL-6) reflecting additional regulatory pathways
that are simultaneously affected by TAK1.
Recently, Courties et al. reported that RNA interference-
mediated knockdown of myeloid cell derived-TAK1 ameliorates
inflammation and bone damage in collagen-induced arthritis [15],
a finding that could raise interest in targeting TAK1 in chronic
inflammatory diseases, such as rheumatoid arthritis. Further
analysis revealed that knockdown of myeloid TAK1 directly
attenuated Th1 responses, which play a significant role in
mediating inflammation and development of collagen-induced
arthritis, highlighting a modulatory role for myeloid-specific
TAK1 in the adaptive immune response. Similar to our present
results, in the study by Courties et al. [15] , LPS-induced JNK
activation was also found to be reduced in a mouse monocytic cell
line that was transiently transfected with siRNAs against TAK1.
However, in the same study, despite a downregulated systemic
proinflammatory response, the myeloid-specific contribution in
proinflammatory cytokines was not addressed. It would be
interesting to compare myeloid-specific cytokine responses in a
chronic setting, such as in the collagen-induced arthritis model,
with the enhanced acute myeloid response that we have observed
with LPS. Our study combined with previous findings highlights a
context and tissue dependence of the proinflammatory and
antiinflammatory functions of TAK1 that could have implications
for the future development of therapeutic concepts targeting
TAK1 function in human inflammatory disease.
Table 1. Immunophenotypical flow cytometric analysis of
BM, peripheral blood, spleen and peritoneal cavity myeloid
cells in Map3k7
Dmyel and Map3k7
flox/flox mice.
Map3k7
flox/flox
(n=7–8)
Map3k7
Dmyel
(n=7)
BM (610
9)
CMPs (Lin
2c-Kit
+Sca-1 CD16/32
loCD34
+)1 . 4 60.4 1.360.3
GMPs (Lin
2c-Kit
+Sca-1
2CD16/32
hiCD34
+)2 . 4 60.5 2.260.3
Gran/Mac fraction (Gr1
+/CD11b
+)1 . 5 60.3 1.560.1
Peripheral Blood (%)
Monocytes (CD11b
+Ly6C
hi)0 . 9 60.3 1.460.6
Neutrophils (CD11b
+Ly6C
loGr1
hi)3 . 3 60.7 2.761.5
Spleen (610
6)
Macrophages (F4/80
+)1 3 4 649 137678
Neutrophils (CD11b
+Gr1
+)1 0 0 645 1866144
Peritoneal cavity (610
6)
Resident macrophages (CD11b
+F4/80
+)5 6 617 60619
Mean values 6 SD obtained from the indicated number of mice (n) are given.
Measurements are a pool of two independent experiments. CMPs, common
myeloid progenitors; GMPs, granulocyte/macrophage progenitors.
doi:10.1371/journal.pone.0031550.t001
Figure 2. Impaired activation of NF-kB and JNK in response to
LPS stimulation in TAK1-deficient macrophages. BMDMs were
stimulated with LPS (100 ng/ml) and nuclear/cytoplasmic extracts were
collected at the indicated times. (A) NF-kB DNA-binding activity in
nuclear extracts was determined by EMSA. The lysates used for EMSA
were subjected to immunoblot analysis using a TFIIB-specific antibody
as a loading control. (B) Phosphorylation of JNK (p-JNK) in cytoplasmic
extracts was assessed by immunoblot with antibody specific for its
phosphorylated form. The membrane was reprobed for total JNK.
Results are representative of three independent experiments.
doi:10.1371/journal.pone.0031550.g002
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PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31550Figure 3. Enhanced inflammatory cytokine profile in TAK1-deficient macrophages and neutrophils in response to LPS. (A–D) BMDMs
and (E–H) thioglycollate-elicited peritoneal neutrophils from Map3k7
Dmyel and Map3k7
flox/flox mice were stimulated with 100 ng/ml LPS. (A, E) IL-1b,
(B, F) TNF, (C, G) IL-6, and (D, H) IL-10 production were measured in cell culture supernatants by ELISA. (A–H) Data are representative of three
independent experiments with 4 mice per group and are shown as mean 6 SEM.
*,p #0.05;
**,p #0.01;
***,p #0.005.
doi:10.1371/journal.pone.0031550.g003
Figure 4. Increased LPS-induced mortality and altered circulating cytokine levels in mice deficient in myeloid TAK1. (A) IL-1b, (B) TNF,
(C) IL-6, and (D) IL-10 serum levels after LPS administration (100 ı `g/mouse) in Map3k7
Dmyel and Map3k7
flox/flox mice. Data are represented as mean 6
SEM of 8–15 mice, pooled from three independent experiments.
*,p #0.05;
**,p #0.01;
***,p #0.005. (E) Survival of Map3k7
Dmyel (n=16), Map3k7
flox/flox
(n=15) and LysM-Cre (n=5) mice after LPS injection (20 mg/kg).
doi:10.1371/journal.pone.0031550.g004
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Ethics Statement
All animal experiments conformed to all current national and
European legislation and were approved by the Prefecture of
Attica (approval ID 1463A) and by the Institutional Animal Care
and Use Committee of the Biomedical Sciences Research Center
‘‘Alexander Fleming’’ (approval ID 2350B).
Generation of conditional TAK1-deficient mice
For the generation of conditional TAK1-deficient mice, a
targeting vector was constructed in which a 0.6 kb fragment of
Map3k7 containing exon 2 was flanked by loxP sites. The targeting
vector also contained an FRT-neo-FRT selection cassette next to
the first loxP site and before exon 2 (Fig. 1A). An upstream 3.3 kb
and a downstream 4.0 kb fragment were used as ‘arms’ for
homology. Bruce-4 ES cells derived from C57BL/6 mice [25]
were cultured, transfected and selected using standard protocols.
Targeted ES cell clones were selected by Southern blotting with 59
and 39 probes, after digestion with SacI and BamHI respectively.
The FRT-neo-FRT selection cassette was excised using flipper
mice [26]. Generation of heterozygous floxed Map3k7 mice
(Map3k7
flox/+) was carried out by following standard procedures.
The mice used in this study were 6–12 wks old and were
maintained on a C57BL/6 genetic background. All mice were
housed under specific pathogen-free conditions.
Progenitor cell assays
Colony-forming assays were performed by plating single cell
suspensions of BM (3–5610
4 cells/ml) in triplicate in 1 ml
methylcellulose medium in 35 mm Petri dishes. Cells were
incubated for 8 days in methylcellulose medium containing GM-
CSF (MethoCult M3001) or incomplete methylcellulose medium
(MethoCult M3231, Stem Cell Technology) supplemented with
10 ng/ml G-CSF or M-CSF (PeproTech). Colonies were scored
on day 8.
Flow cytometric analysis
Single cell suspensions were prepared from BM, blood, spleen
and peritoneal cavity. Where required, red blood cells were
excluded by Gey’s lysis solution and debris was removed by cell
strainer (70 mm, BD Falcon). After blockade of Fc-receptors with
CD16/32 blocking antibody, cells were stained with antibodies
conjugated with fluorochromes for 30 min on ice and washed
twice before FACS analysis. For antibodies not directly conjugated
to fluorochromes, staining with a secondary antibody was required
for 20–30 min on ice, followed by a wash step. Data were collected
by FACS Canto II and analyzed by using FACS Diva software
(Becton Dickinson). For cell sorting a FACS Vantage SE II was
used (Becton Dickinson). Cells were labelled using monoclonal
antibodies against: CD11b (M1/70, BD Biosciences), Gr1 (RB6-
8C5, e-Bioscience), F4/80 (BM8, e-Bioscience), Ly-6C (AL-21, BD
Biosciences), c-Kit (2B8, e-Bioscience), Sca-1 (D7, e-Bioscience),
TER-119 (TER119, e-Bioscience), B220 (RA3-6B2, e-Bioscience),
CD3e (145-2C11, e-Bioscience), CD34 (RAM34, e-Bioscience),
CD16/32 (93, e-Bioscience); these antibodies are conjugated with
different markers, such as fluorescein isothiocyanate (FITC),
phycoerythrin (PE), allophycocyanin (APC), APC-Alexa750,
Alexa700, PE-Cy5.5 or biotin. Streptavidin coupled to FITC or
APC (BD Biosciences) was used as a secondary antibody.
Cell cultures
For BMDMs preparation, BM cells were cultured in complete
RPMI in the presence of 20% medium conditioned by L929
mouse fibroblasts (as a source of M-CSF). On day 8, BMDMs
were collected and used as indicated. To isolate neutrophils,
mice were i.p. injected with 1 ml of 4% thioglycollate
(DIFCO) and peritoneal neutrophils were flushed out 3–5 h
later. The percentages of neutrophils in the peritoneal cell
populations were similar between Map3k7
Dmyel (83,464,2, n=3)
and Map3k7
flox/flox (82,065,7, n=3) littermates as analyzed by
flow cytometry.
Immunoblot analysis
Proteins were resolved by SDS PAGE and were transferred to
nitrocellulose membranes by electroblot. Non-specific binding sites
were blocked by incubation in 10 mM Tris-HCl pH 7.5, 150 mM
NaCl, containing 0.5% Tween-20 and 5% dry milk. Membranes
were blotted with antibodies against p-JNK (#46685, Cell
Signaling), JNK (sc-7345, Santa Cruz) and TFIIB (sc-225, Santa
Cruz) according to the manufacturer’s instructions for each
antibody.
EMSA
Nuclear extracts were prepared and EMSA was performed as
previously described [27]. The sequences of the oligonucleotides
used for NF-kB with two tandemly positioned NF-kB binding sites
(underlined) were as follows: NF-kBF (59-ATCAGGGACTT-
TCCGCTGGGGACTTT-39) and NF-kBR (59-CGGAAAGTC-
CCCAGCGGAAAGTCCCT-39).
Endotoxemia
Mice (8–12 wks) were i.p. injected with a sublethal dose
(20 mg/kg) of LPS (Escherichia coli 0111:B4, Sigma) and were
monitored for survival. For serum cytokine measurements, mice
were i.p. injected with 100 mg of LPS and at indicated time points
were euthanized and blood serum was collected.
Cytokine ELISA measurements
Serum cytokine levels and cytokines secreted from primary cells
were determined by ELISA. Macrophages were plated in
duplicate per mouse at 5610
5 cells/well in 24-well plates and
were allowed to adhere for 3 h before stimulation. Neutrophils
isolated from 4 mice were pooled and plated in quadruplicate at
1610
6 cells/well in 24-well plates. Cells were stimulated with
100 ng/ml LPS for the times indicated, followed by incubation
with 1 mM ATP for 30 min for IL-1b measurements, and
supernatants were taken for cytokine measurements. ELISA kits
for TNF, IL-6, IL-10 (e-Bioscience) and IL-1b (BD Biosciences)
were used according to manufacturer’s instructions.
Statistical analysis
Statistical comparisons were performed using unpaired Stu-
dent’s two tailed t test, with p values #0.05 considered statistically
significant.
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